Sunshine Biopharma, Inc.
SBFM
$1.40
-$0.02-1.41%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 36.34M | 36.23M | 34.87M | 32.96M | 30.48M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 36.34M | 36.23M | 34.87M | 32.96M | 30.48M |
| Cost of Revenue | 24.23M | 25.19M | 24.20M | 22.81M | 21.21M |
| Gross Profit | 12.11M | 11.05M | 10.67M | 10.14M | 9.27M |
| SG&A Expenses | 16.20M | 15.16M | 14.89M | 12.90M | 11.62M |
| Depreciation & Amortization | 267.30K | 245.70K | 223.50K | 200.50K | 173.10K |
| Other Operating Expenses | 388.20K | 421.30K | 387.00K | 355.00K | 351.10K |
| Total Operating Expenses | 41.77M | 41.94M | 40.64M | 37.87M | 35.07M |
| Operating Income | -5.43M | -5.71M | -5.76M | -4.91M | -4.59M |
| Income Before Tax | -6.47M | -5.33M | -5.37M | -4.11M | -3.74M |
| Income Tax Expenses | -162.90K | -297.40K | -234.80K | 114.20K | -60.00K |
| Earnings from Continuing Operations | -6.31 | -5.03 | -5.13 | -4.23 | -3.68 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.31M | -5.03M | -5.13M | -4.23M | -3.68M |
| EBIT | -5.43M | -5.71M | -5.76M | -4.91M | -4.59M |
| EBITDA | -5.17M | -5.46M | -5.54M | -4.71M | -4.41M |
| EPS Basic | -2.78 | -12.33 | -13.89 | -98.87 | -148.64 |
| Normalized Basic EPS | -1.56 | -11.96 | -12.91 | -56.52 | -85.74 |
| EPS Diluted | -2.78 | -12.33 | -13.89 | -98.87 | -148.65 |
| Normalized Diluted EPS | -1.56 | -11.96 | -12.91 | -56.52 | -85.74 |
| Average Basic Shares Outstanding | 10.62M | 6.17M | 4.11M | 1.97M | 718.30K |
| Average Diluted Shares Outstanding | 10.62M | 6.17M | 4.11M | 1.97M | 718.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |